Harrow Health Inc.

NAS: HROW

GO
/marketstate/country/us

Market open

 --Real time quotes

Jan 27, 2023, 10:36 a.m.

/zigman2/quotes/206805265/composite

$

14.91

Change

+0.44 +3.04%

Volume

Volume 15,217

Real time quotes

/zigman2/quotes/206805265/composite

Previous close

$ 14.47

$ 14.91

Change

+0.44 +3.04%

Day low

Day high

$14.41

$14.91

Open

52 week low

52 week high

$5.40

$15.59

Open

Insider Actions for Harrow Health Inc.

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
12/22/2022 Mark L. Baum
Chief Executive Officer; Director
25,000   Acquisition at $13.39 per share. 334,750
12/22/2022 Andrew R. Boll
Chief Financial Officer
2,500   Acquisition at $13.54 per share. 33,850
12/22/2022 R. Lawrence van Horn
Director
1,860   Acquisition at $13.42 per share. 24,961
12/21/2022 Martin A. Makary
Director
25,000   Acquisition at $13.37 per share. 334,250
12/14/2022 Opaleye Management, Inc.
16,183   Acquisition at $10.52 per share. 170,245
12/14/2022 Opaleye Management, Inc.
415,000   Acquisition at $10.52 per share. 4,365,800
09/30/2022 Richard L. Lindstrom
Director
40,000   Disposition at $12.62 per share. 504,800
09/28/2022 Opaleye Management, Inc.
1,085   Acquisition at $9.77 per share. 10,600
09/28/2022 Opaleye Management, Inc.
10,000   Acquisition at $9.77 per share. 97,700
04/13/2022 Opaleye Management, Inc.
2,832   Acquisition at $6.76 per share. 19,144
04/13/2022 Opaleye Management, Inc.
10,000   Acquisition at $6.76 per share. 67,600
04/12/2022 Opaleye Management, Inc.
3,557   Acquisition at $6.75 per share. 24,009
04/12/2022 Opaleye Management, Inc.
25,000   Acquisition at $6.75 per share. 168,750
02/19/2022 Andrew R. Boll
Chief Financial Officer
20,605   Derivative/Non-derivative trans. at $7.87 per share. 162,161
02/19/2022 John P. Saharek
President, ImprimisRx
25,923   Derivative/Non-derivative trans. at $7.87 per share. 204,014
02/19/2022 Andrew R. Boll
Chief Financial Officer
50,000   Derivative/Non-derivative trans. at $0 per share. 0
02/19/2022 John P. Saharek
President, ImprimisRx
50,000   Derivative/Non-derivative trans. at $0 per share. 0
01/28/2022 Opaleye Management, Inc.
1,343   Acquisition at $6.89 per share. 9,253
01/28/2022 Opaleye Management, Inc.
5,000   Acquisition at $6.89 per share. 34,450
01/20/2022 Mark L. Baum
Chief Executive Officer; Director
71,406   Derivative/Non-derivative trans. at $8.33 per share. 594,811
01/20/2022 Mark L. Baum
Chief Executive Officer; Director
125,000   Derivative/Non-derivative trans. at $2.4 per share. 300,000

Transaction Summary

Total insider purchases and sales reported to the SEC

Timeframe Transactions Shares
Last 3 months
6 Purchases
0 Sales
485,543
0
Last 6 months
8 Purchases
1 Sales
496,628
40,000
Last 12 months
16 Purchases
3 Sales
644,360
86,528

Officers and Executives

Mr. Mark L. Baum
Chairman & Chief Executive Officer
Mr. Andrew R. Boll
Chief Financial Officer & Secretary
Dr. Larry M. Dillaha
Chief Medical Officer
Mr. Andrew Livingston
Chief Innovation Officer
Mr. John P. Saharek
President-ImprimisRx
Dr. Richard L. Lindstrom
Director
Ms. Teresa F. Sparks
Independent Director
Dr. R. Lawrence van Horn
Independent Director
Mr. Perry J. Sternberg
Independent Director
Dr. Marty Makary
Independent Director
Link to MarketWatch's Slice.